Cost-effectiveness analysis of tepotinib vs capmatinib as subsequent therapy in MET exon 14-mutated non-small-cell lung cancer

Puntos clave

• This analysis aims to evaluate the cost-effectiveness of tepotinib compared to capmatinib as a second-line treatment for NSCLC.
• Conducted a cost-effectiveness analysis between tepotinib and capmatinib.
• Targeted population includes patients with advanced or metastatic non-small cell lung cancer.
• Compared treatment costs and outcomes in a Chinese healthcare setting.
• Tepotinib was found to be less cost-effective than capmatinib.
• Capmatinib is recommended as the preferable second-line treatment option for economic reasons.